PDF herunterladen
CC BY 4.0 · Semin Reprod Med 2024; 42(01): 049-059
DOI: 10.1055/s-0044-1786731
Review Article

Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis

Terhi T. Piltonen   *
1   Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland
,
Johanna Viita-aho
1   Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland
,
Ulla Saarela
1   Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Medical Research Center Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland
,
Johanna Melin   *
2   Department of Obstetrics and Gynecology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
,
Maria Forslund   *
3   Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
› Institutsangaben Funding This study relates to grants from the Finnish Medical Foundation (T.T.P.), the Academy of Finland (project grants 315921, 321763, T.T.P.), Oulu University Hospital regional fund (T.T.P.), the Sigrid Juselius Foundation (T.T.P.), Novo Nordisk Foundation (T.T.P.), the Finnish Cultural Foundation (T.T.P.), Finska Läkaresällskapet (J.M.), Swedish Medical Society (SLS-984944, M.F.). T.T.P. has received funding from Roche Diagnostics for AMH-related researcher-initiated studies.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

The 2023 international evidence-based guideline update for the assessment and management of polycystic ovary syndrome (PCOS) recommends using the Rotterdam criteria for the diagnosis of PCOS. The updated guideline has evidence-based recommendation for the diagnosis, and it now also includes serum anti-Müllerian hormone (AMH) measurement as an alternative tool for gynecological ultrasound to diagnose polycystic ovary morphology (PCOM). The aim of this new recommendation was to facilitate PCOS diagnostic workup in primary care and other disciplines, as currently most diagnosing is done in gynecology and infertility clinics. Here, we review factors affecting AMH levels as well as the utility of AMH in PCOS diagnosis. We identified relevant studies that report different cut-offs for AMH to diagnose PCOM as part of PCOS diagnosis. There are, however, some limitations when using AMH that should be acknowledged. These include physiological aspects like age, ethnicity, and obesity and iatrogenic causes like hormonal medication and ovarian surgery. Also reference ranges are different depending on AMH assay used. As a summary, we conclude that AMH is a usable tool in PCOM diagnostics, but it does not have a single cut-off. Therefore, further studies are needed to establish age and assay-based reference ranges.

Keywords

PCOS - PCOS diagnosis - AMH

* Equal contribution as senior author.




Publikationsverlauf

Artikel online veröffentlicht:
22. Mai 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Teede HJ, Tay CT, Laven JJE. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 2023; 108 (10) 2447-2469
    CrossrefPubMedSuche in Google Scholar
  • 2 Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 2021; 106 (03) e1071-e1083
    CrossrefPubMedSuche in Google Scholar
  • 3 Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14 (05) 270-284
    CrossrefPubMedSuche in Google Scholar
  • 4 Karjula S, Morin-Papunen L, Auvinen J. et al. Psychological distress is more prevalent in fertile age and premenopausal women with PCOS symptoms: 15-year follow-up. J Clin Endocrinol Metab 2017; 102 (06) 1861-1869
    CrossrefPubMedSuche in Google Scholar
  • 5 Alur-Gupta S, Dokras A. Considerations in the treatment of depression and anxiety in women with PCOS. Semin Reprod Med 2023; 41 (1-02): 37-44
    Thieme ConnectPubMedSuche in Google Scholar
  • 6 Bahri Khomami M, Joham AE, Boyle JA. et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity - a systematic review, meta-analysis, and meta-regression. Obes Rev 2019; 20 (05) 659-674
    CrossrefPubMedSuche in Google Scholar
  • 7 Sagvekar P, Dadachanji R, Patil K, Mukherjee S. Pathomechanisms of polycystic ovary syndrome: multidimensional approaches. Front Biosci (Elite Ed) 2018; 10 (03) 384-422
    CrossrefPubMedSuche in Google Scholar
  • 8 Rowlands IJ, Teede H, Lucke J, Dobson AJ, Mishra GD. Young women's psychological distress after a diagnosis of polycystic ovary syndrome or endometriosis. Hum Reprod 2016; 31 (09) 2072-2081
    CrossrefPubMedSuche in Google Scholar
  • 9 Presswala B, De Souza LR. The diagnostic experience of polycystic ovary syndrome: a scoping review of patient perspectives. Patient Educ Couns 2023; 113: 107771
    CrossrefPubMedSuche in Google Scholar
  • 10 Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447
    CrossrefPubMedSuche in Google Scholar
  • 11 Joham AE, Norman RJ, Stener-Victorin E. et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022; 10 (09) 668-680
    CrossrefPubMedSuche in Google Scholar
  • 12 Sova H, Unkila-Kallio L, Tiitinen A. et al. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol 2019; 35 (07) 595-600
    CrossrefPubMedSuche in Google Scholar
  • 13 Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can 2008; 30 (08) 671-679
    CrossrefPubMedSuche in Google Scholar
  • 14 Azziz R, Carmina E, Dewailly D. et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11) 4237-4245
    CrossrefPubMedSuche in Google Scholar
  • 15 Weenen C, Laven JSE, Von Bergh ARM. et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10 (02) 77-83
    CrossrefPubMedSuche in Google Scholar
  • 16 Dewailly D, Andersen CY, Balen A. et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014; 20 (03) 370-385
    CrossrefPubMedSuche in Google Scholar
  • 17 Barbotin AL, Peigné M, Malone SA, Giacobini P. Emerging roles of anti-Müllerian hormone in hypothalamic-pituitary function. Neuroendocrinology 2019; 109 (03) 218-229
    CrossrefPubMedSuche in Google Scholar
  • 18 Cimino I, Casoni F, Liu X. et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun 2016; 7: 10055
    CrossrefPubMedSuche in Google Scholar
  • 19 Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20 (07) 1820-1826
    CrossrefPubMedSuche in Google Scholar
  • 20 Depmann M, Eijkemans MJC, Broer SL. et al. Does AMH relate to timing of menopause? Results of an individual patient data meta- analysis. J Clin Endocrinol Metab 2018;
    CrossrefPubMedSuche in Google Scholar
  • 21 Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-Mullerian hormone. J Clin Endocrinol Metab 2013; 98 (02) 729-735
    CrossrefPubMedSuche in Google Scholar
  • 22 Pilsgaard F, Grynnerup AGA, Løssl K, Bungum L, Pinborg A. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling. Acta Obstet Gynecol Scand 2018; 97 (09) 1105-1113
    CrossrefPubMedSuche in Google Scholar
  • 23 Teede H, Misso M, Tassone EC. et al. Anti-Müllerian hormone in PCOS: a review informing international guidelines. Trends Endocrinol Metab 2019; 30 (07) 467-478
    CrossrefPubMedSuche in Google Scholar
  • 24 Li HWR, Robertson DM, Burns C, Ledger WL. Challenges in measuring AMH in the clinical setting. Front Endocrinol (Lausanne) 2021; 12: 691432
    CrossrefPubMedSuche in Google Scholar
  • 25 Li HWR, Wong BPC, Ip WK, Yeung WSB, Ho PC, Ng EHY. Comparative evaluation of three new commercial immunoassays for anti-Müllerian hormone measurement. Hum Reprod 2016; 31 (12) 2796-2802
    CrossrefPubMedSuche in Google Scholar
  • 26 Moolhuijsen LME, Louwers YV, Laven JSE, Visser JA. Comparison of 3 different AMH assays with AMH levels and follicle count in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2022; 107 (09) e3714-e3722
    CrossrefPubMedSuche in Google Scholar
  • 27 Piltonen TT, Allegranza D, Hund M, Buck K, Sillman J, Arffman RK. Validation of an anti-Müllerian hormone cutoff for polycystic ovarian morphology in the diagnosis of polycystic ovary syndrome in the HARMONIA study: protocol for a prospective, noninterventional study. JMIR Res Protoc 2024; 13 (13) e48854
    CrossrefPubMedSuche in Google Scholar
  • 28 Laven JSE, Mulders AGMGJ, Visser JA, Themmen AP, De Jong FH, Fauser BCJM. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89 (01) 318-323
    CrossrefPubMedSuche in Google Scholar
  • 29 Mulders AGMGJ, Laven JSE, Eijkemans MJC, de Jong FH, Themmen APN, Fauser BCJM. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod 2004; 19 (09) 2036-2042
    CrossrefPubMedSuche in Google Scholar
  • 30 Awoke MA, Earnest A, Joham AE. et al. Weight gain and lifestyle factors in women with and without polycystic ovary syndrome. Hum Reprod 2021; 37 (01) 129-141
    CrossrefPubMedSuche in Google Scholar
  • 31 Jaswa EG, Rios JS, Cedars MI. et al. Increased body mass index is associated with a nondilutional reduction in antimüllerian hormone. J Clin Endocrinol Metab 2020; 105 (10) 3234-3242
    CrossrefPubMedSuche in Google Scholar
  • 32 Lim SS, Kakoly NS, Tan JWJ. et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev 2019; 20 (02) 339-352
    CrossrefPubMedSuche in Google Scholar
  • 33 Vagios S, James KE, Sacha CR. et al. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders. Fertil Steril 2021; 115 (01) 229-237
    CrossrefPubMedSuche in Google Scholar
  • 34 Kotlyar AM, Seifer DB. Ethnicity/Race and age-specific variations of serum AMH in women - a review. Front Endocrinol (Lausanne) 2021; 11: 593216
    CrossrefPubMedSuche in Google Scholar
  • 35 Zhang M, Liu X, Xu X. et al. The reference value of anti-Müllerian hormone to diagnose polycystic ovary syndrome is inversely associated with BMI: a retrospective study. Reprod Biol Endocrinol 2023; 21 (01) 15
    CrossrefPubMedSuche in Google Scholar
  • 36 La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool?. Clin Endocrinol (Oxf) 2006; 64 (06) 603-610
    CrossrefPubMedSuche in Google Scholar
  • 37 Biniasch M, Laubender RP, Hund M, Buck K, De Geyter C. Intra- and inter-cycle variability of anti-Müllerian hormone (AMH) levels in healthy women during non-consecutive menstrual cycles: the BICYCLE study. Clin Chem Lab Med 2021; 60 (04) 597-605
    CrossrefPubMedSuche in Google Scholar
  • 38 Arffman RK, Saraswat M, Joenväärä S. et al. Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics. Sci Rep 2019; 9 (01) 17578
    CrossrefPubMedSuche in Google Scholar
  • 39 Tata B, Mimouni NEH, Barbotin AL. et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 2018; 24 (06) 834-846
    CrossrefPubMedSuche in Google Scholar
  • 40 Valdimarsdottir R, Valgeirsdottir H, Wikström AK. et al. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels. Reprod Biomed Online 2019; 39 (01) 141-148
    CrossrefPubMedSuche in Google Scholar
  • 41 Piltonen TT, Giacobini P, Edvinsson Å. et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril 2019; 111 (03) 588-596.e1
    CrossrefPubMedSuche in Google Scholar
  • 42 La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005; 20 (06) 1569-1572
    CrossrefPubMedSuche in Google Scholar
  • 43 Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril 2010; 93 (04) 1356-1358
    CrossrefPubMedSuche in Google Scholar
  • 44 McCredie S, Ledger W, Venetis CA. Anti-Müllerian hormone kinetics in pregnancy and post-partum: a systematic review. Reprod Biomed Online 2017; 34 (05) 522-533
    CrossrefPubMedSuche in Google Scholar
  • 45 McCredie S, An B, McShane M, Ledger WL, Venetis C. Serum anti-müllerian hormone (AMH) concentration during pregnancy: a longitudinal study. Reprod Fertil 2023; 4 (02) RAF-22-RAF-0128
    CrossrefPubMedSuche in Google Scholar
  • 46 Hariton E, Shirazi TN, Douglas NC, Hershlag A, Briggs SF. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals. Am J Obstet Gynecol 2021; 225 (05) 515.e1-515.e10
    CrossrefPubMedSuche in Google Scholar
  • 47 Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013; 99 (05) 1305-1310
    CrossrefPubMedSuche in Google Scholar
  • 48 Kwon SK, Kim SH, Yun SC. et al. Decline of serum antimüllerian hormone levels after laparoscopic ovarian cystectomy in endometrioma and other benign cysts: a prospective cohort study. Fertil Steril 2014; 101 (02) 435-441
    CrossrefPubMedSuche in Google Scholar
  • 49 Lind T, Hammarström M, Lampic C, Rodriguez-Wallberg K. Anti-Müllerian hormone reduction after ovarian cyst surgery is dependent on the histological cyst type and preoperative anti-Müllerian hormone levels. Acta Obstet Gynecol Scand 2015; 94 (02) 183-190
    CrossrefPubMedSuche in Google Scholar
  • 50 Ahmed N, Batarfi AA, Bajouh OS, Bakhashab S. Serum anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome in association with clinical symptoms. Diagnostics (Basel) 2019; 9 (04) 136
    CrossrefPubMedSuche in Google Scholar
  • 51 Bansal P, Sardana K, Arora P, Khurana A, Garga UC, Sharma L. A prospective study of anti-Mullerian hormone and other ovarian and adrenal hormones in adult female acne. Dermatol Ther 2020; 33 (06) e13974
    CrossrefPubMedSuche in Google Scholar
  • 52 Bell RJ, Islam RM, Skiba MA, Herbert D, Martinez Garcia A, Davis SR. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod 2021; 37 (01) 109-118
    CrossrefPubMedSuche in Google Scholar
  • 53 Dewailly D, Gronier H, Poncelet E. et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26 (11) 3123-3129
    CrossrefPubMedSuche in Google Scholar
  • 54 Dietz de Loos A, Hund M, Buck K, Meun C, Sillman J, Laven JSE. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril 2021; 116 (04) 1149-1157
    CrossrefPubMedSuche in Google Scholar
  • 55 Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?. Hum Reprod 2012; 27 (08) 2494-2502
    CrossrefPubMedSuche in Google Scholar
  • 56 Lauritsen MP, Bentzen JG, Pinborg A. et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 2014; 29 (04) 791-801
    CrossrefPubMedSuche in Google Scholar
  • 57 Li Y, Ma Y, Chen X. et al. Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. J Assist Reprod Genet 2012; 29 (10) 1147-1151
    CrossrefPubMedSuche in Google Scholar
  • 58 Matsuzaki T, Munkhzaya M, Iwasa T. et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J 2017; 64 (05) 531-541
    CrossrefPubMedSuche in Google Scholar
  • 59 Piltonen TT, Komsi E, Morin-Papunen LC. et al. AMH as part of the diagnostic PCOS workup in large epidemiological studies. Eur J Endocrinol 2023; 188 (06) 547-554
    CrossrefPubMedSuche in Google Scholar
  • 60 Ramezani Tehrani F, Rahmati M, Mahboobifard F, Firouzi F, Hashemi N, Azizi F. Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome. Reprod Biol Endocrinol 2021; 19 (01) 76
    CrossrefPubMedSuche in Google Scholar
  • 61 Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet 2014; 31 (02) 213-220
    CrossrefPubMedSuche in Google Scholar
  • 62 Saxena U, Ramani M, Singh P. Role of AMH as diagnostic tool for polycystic ovarian syndrome. J Obstet Gynecol India 2018; 68 (02) 117-122
    CrossrefPubMedSuche in Google Scholar
  • 63 Sumji S, Bhat A, Rashid A. et al. Efficacy of serum anti-Mullerian hormone (AMH) levels for prediction of polycystic ovary syndrome (PCOS) and its association with clinical, biochemical and hormonal parameters. Indian J Clin Biochem 2023; 38 (04) 457-465
    CrossrefPubMedSuche in Google Scholar
  • 64 Pigny P, Merlen E, Robert Y. et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88 (12) 5957-5962
    CrossrefPubMedSuche in Google Scholar
  • 65 Teede HJ, Misso ML, Costello MF. et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018; 33 (09) 1602-1618
    CrossrefPubMedSuche in Google Scholar